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INTRODUCTION
In Indonesia, contraceptive injections ranked first
as the most common contraceptive methods cho-
sen by the community. Data from BKKBN, in 2007,
showed that the number of active injection user
was 3,000,483 (55.55%). The reasons that people
prefer injection are because of its low compliance,
inexpensive price and low failure rate.1 But, a re-
cent epidemiological studies suggested a possible
increased risk of diabetes incidence in DMPA users.
DMPA is associated with weight gain, which is one
of the risk factor for type 2 diabetes mellitus. This
is indicated by the rising insulin level in response
to contraceptive injections, causing patients with
risk factors to fall into a state of glucose intoleran-
ce.2-4
One of the side effects of giving a single pro-
gestin contraceptive injection is an increase of the
concentration of progesterone excessively in the
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Objective: To study the relationship between the history of contra-
ceptive injection depo medroxyprogesterone acetate (DMPA) expo-
sure with incidence of diabetes mellitus and the associated risk fac-
tors.
Methods: This is a case-control study conducted in 6 Public Health
Centers in East Jakarta involving 30 cases of diabetes mellitus and 61
controls. Body mass index (BMI), parity, type of contraception, dura-
tion of contraceptive use, history of gestational diabetes and breast-
feeding were assessed in each group. Data were analyzed with Chi
Square or Fisher’s test, and logistic regression.
Results: The mean age of the subjects was 45.00 (35-67) years, with
a median number of parity of 3.00 (0-7), and the median of BMI was
27.31 (15.24 to 40.27). The number of DMPA injections users was
31.9% and the mean duration of contraception usage was 5.36 ±
4.42 years. There was a correlation between the history of DMPA in-
jections with incidence of diabetes mellitus, with an odds ratio of
3.36 95% CI [1.098 to 10.469]. The risk persisted after adjustment
of age and BMI.
Conclusion: DMPA exposure was associated with a greater risk of
diabetes mellitus. Risk was associated with length of use and persis-
ted after adjusment with age and BMI.
[Indones J Obstet Gynecol 2012; 36-2: 100-4
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Abstrak
Tujuan: Mengetahui hubungan antara riwayat pajanan kontrasepsi
suntikan depo medroksiprogesteron asetat (DMPA) dengan diabetes
melitus dan faktor-faktor risiko yang mempengaruhinya.
Metode: Penelitian kasus kontrol dilakukan di 6 Puskesmas Jakarta
Timur dengan mengambil 30 kasus diabetes mellitus dan 61 kontrol.
Indeks massa tubuh (IMT), paritas, jenis kontrasepsi, lama penggu-
naan kontrasepsi, riwayat diabetes gestasional dan menyusui dinilai
pada masing-masing kelompok. Data dianalisis dengan chi square
atau fisher’s test dan regresi logistik.
Hasil: Karakteristik sampel dengan usia 45,00 (35-67) tahun, riwayat
paritas dengan nilai median 3,00 (0-7), dengan IMT nilai median
27,31 (15,24-40,27). Jumlah pengguna kontrasepsi suntikan DMPA se-
besar 31,9% dan rerata lama penggunaan kontrasepsi 5,36±4,42 ta-
hun. Terdapat hubungan penggunaan kontrasepsi suntikan DMPA
dengan kejadian diabetes mellitus, dengan odd ratio 3,36 95% CI
[1,098-10,469]. Setelah dilakukan penyesuaian pada usia dan IMT,
risiko turun namun tetap bertahan.
Kesimpulan: DMPA dikaitkan dengan risiko lebih besar menderita
diabetes melitus. Risiko berkaitan dengan lamanya penggunaan dan
menetap meskipun dilakukan penyesuaian pada usia dan IMT.
[Maj Obstet Ginekol Indones 2012; 36-2: 100-4]
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blood. Excess of progesterone in the blood affects
the tolerance to glucose and sensitivity to insulin
sensitivity.5-6
A similar phenomenon is found in the mecha-
nism of Gestational Diabetes Mellitus (GDM). Into-
lerance to glucose in patients with GDM starts to
be found at 26th week of pregnancy and increased
significantly at 32nd week of pregnancy. The 32nd
week of pregnancy is the culmination of blood pro-
gesterone concentration maintained until the birth
process.7-9
The state of insulin resistance on the use of
DMPA is similar to the state of insulin resistance
in pregnancy. In normal pregnancy, there is a pro-
gressive insulin resistance that occurs in the third
trimester, with a resistance level similar to that of
individuals with type 2 diabetes.4 Insulin sensitiv-
ity is reduced by 80%. Secretion of placental hor-
mones such as progesterone, cortisol, placental lac-
togen, prolactin, growth hormone gave a major
contribution in a state of insulin resistance in preg-
nancy. This insulin resistance aim to ensure the fe-
tus obtaining an adequate supply of glucose and to
alter maternal energy metabolism from carbohy-
drate to fat. Women with gestational diabetes have
more severe degree of insulin resistance when
compared with women with normal pregnancies.
Women with gestational diabetes are susceptible
to increase the compensation of insulin secretion.
The decreasing insulin release showed deteriora-
tion of pancreatic beta cell function.8,9
DMPA injections users that have experienced
disturbances in insulin metabolism have an in-
creased risk to develop type 2 diabetes mellitus.
This increased risk may be caused by several fac-
tors, such as initial body weight prior to the use of
DMPA, the status of breast-feeding after birth, his-
tory of gestational diabetes in previous pregnan-
cies, family history of diabetes mellitus and lipid
profiles. All of these can increase the risk of DMPA
users to suffer diabetes mellitus.10
METHODS
This was a case-control study, aimed to determine
the relationship between the incidence of type 2
diabetes mellitus and DMPA injections exposure
history and risk factors associated.
The study was conducted in 6 health centers in
East Jakarta: Kramat Jati Health Center, Cakung
Health Center, Ciracas Health Center, Pulogadung
Health Center, Duren Sawit Health Center, and
Makassar Health Center. The study was conducted
from January 1, 2012 to March 31, 2012.
Primary data was taken from medical records
regarding the diagnosis in patients with type 2 DM
and a history of contraceptive use. If the data on
the medical record was not complete, then we in-
terviewed the respondents.
The estimated sample number was calculated
using unpaired categorical analytic formula and we
obtained the amount of sample for the case was
29, while for the control was 58.
Subjects were patients who came to the health
center and gave approval to participate in the re-
search. The data, such as age, body mass index, pa-
rity, lactation status, methods and duration of con-
traceptive use, were collected through medical re-
cords and interviews. Existing data was processed
using SPSS 17 and presented in a narrative, tabular,
and graphics.
RESULTS
The data was collected at six health centers in East
Jakarta and we obtained 30 sample cases and 61
control samples with an age range between 35-60
years.
Table 1 shows the data of body mass index, with
54 people (59.3%) were overweight. From 70 sub-
jects who use hormonal contraceptives, most were
DMPA injection users (31.9%). From all subjects,
only 12 subjects (13.2%) had a history of gesta-
tional diabetes mellitus.
Table 1. Subject Characteristics
Characteristics Freq (%)
Health center
• Ciracas  7  7.7
• Kramat jati 21 23.1
• Pulogadung 15 16.5
• Makassar 14 15.4
• Duren Sawit 16 17.6
• Cakung 18 19.8
Body mass index
• Normal 37 40.7
• Overweight 54 59.3
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Oral combination pill 18 19.8
Combination injection 11 12.1
DMPA injection 29 31.9
Implant 10 11.0
Mini pill  2  2.2
• Non Hormonal
Calendar method  4  4.4
Condom  4  4.4
IUD  8  8.8
Sterilization  5  5.5
Diabetes Mellitus status
• DM 30 33.0
• No DM 61 67.0
History of Gestational DM
• Yes 12 13.2
• No 79 86.8
Table 2. Duration of DMPA injection use and the relation-
ship with the incidence of diabetes mellitus
Duration
(years) DM (%) No DM (%) Total (%)
> 3 10 62.5  2 15.4 12 41.4
< 3  6 37.5 11 84.6 17 58.6
p 0.022* OR 9.167 95CI [1.189-88.908]
*Fisher Exact test
Table 2 described the duration of DMPA injec-
tion use and its relationship to the incidence of dia-
betes mellitus. Calculated with Chi Square, the p
value was 0.022 (p <0.05), meaning that statisti-
cally there was an association between the dura-
tion of DMPA injection use with the incidence of
diabetes mellitus, with OR 9.167 95CI [1.189 to
88.908].
Table 3. Correlation of DMPA injections compared to non-
hormonal contraceptive injections of DMPA with the inci-
dence of diabetes mellitus
Type of
hormonal DM (%) No DM (%) Total (%)
DMPA
injection
16 59.3 13 30.2 29  58.6
Non DMPA
injection
11 40.7 30 69.8 41  41.4
Total 27 100.0 43 100.0 70 100.0
p 0.017* OR 3.36 95CI [1.098-10.469]
*Chi square (X2) test
Table 3 described the relationship between
DMPA injection and the incidence of diabetes mel-
litus compared with the use of non-DMPA hormo-
nal injection. From Chi Square test, we obtained the
p value of 0.017 (p <0.05), meaning that there is a
statistically significant association between the use
of DMPA injections with the incidence of diabetes
mellitus, with an Odds Ratio of 3.36 95% CI [1.098
to 10.469].
Table 4. Odds ratio of DMPA injections compared to non-
hormonal contraceptive injections with the incidence of dia-
betes mellitus adjusted for age, BMI, parity and history of
DMG
Variable OR p 95% CI(lower; upper)
Age adjusted 2.590 0.035 1.600; 4.215
Age and BMI adjusted 2.111 0.048 0.533; 3.731
Age, BMI, and parity adjusted 2.087 0.434 0.550; 4.016
Age, BMI, parity and history
of GDM
2.057 0.569 0.475; 3.875
In Table 4, logistic regression test was perfor-
med on the known risk variables for the occur-
rence of diabetes mellitus, namely age, BMI, parity,
history of DMG. The cut off point of age as a risk
of diabetes was assumpt at 45 years old. BMI con-
sidered to have diabetes mellitus risk in over-
weight category ≥ 30. Parity > 3 children are con-
sidered at risk for developing diabetes mellitus.
And history of from DMG is considered as the risk
factor of developing diabetes mellitus. And from
the table, it can be concluded that the risk of dia-
betes mellitus decreased when adjusted for age.
The risk still gradually decreased when adjusted
for BMI, parity and history of DMG respectively.
DISCUSSION
The samples were taken from six health centers in
East Jakarta, with the aim of covering a population-
based health center in East Jakarta. During the pe-
riod January-March 2012, 30 samples of cases and
61 samples of control were collected.
Characteristics distribution of the sample show-
ed that the median of the age was 45.00 (35-67)
years, the median number of parity was 3.00 (0-7),
and the median BMI was 27.31 (15.24 to 40.27).
The number of subjects receiving contraceptive in-
jections of DMPA was 31.9%, which is the highest
percentage of contraceptive methods used. These
data correspond to the characteristics of BKKBN
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data that showed the highest injection rate of con-
traceptive users who reach more than 50%.
The mean duration of use of contraception was
5:36 ± 4:42 years, and it was concluded that there is
a relationship between the duration of DMPA injec-
tions for more than 3 years with the incidence of dia-
betes mellitus, where the risk of diabetes was 9.2
times higher in women using DMPA injection for
more than 3 years. While to compare the contracep-
tive injections of DMPA with other hormonal contra-
ceptives among contraceptive injections of DMPA
gained relationship with the incidence of diabetes
mellitus with p = 0.017 and OR 3.36 [1.098 to
10.469]. This research result similar with research
conducted by Kim C et al on the Navajo woman, they
found there is an increasing number of people with
diabetes mellitus in DMPA injection users. Risk in-
creases with respect to duration of use.11
We use a conditional logistic regression analysis
to eliminate confounders and effect modifiers such
as age, BMI, parity and history of GDM, to get the
most influential variable risk of use of DMPA injec-
tions. After adjustment of the age of the sample,
the risk of diabetes mellitus decreased, and even
further when adjusted for BMI. On the variables
parity and a history of gestational diabetes mellitus
risk continues to decline although the value was
found to be statistically insignificant.
The situation above can be explained by the fact
that the subjects with insulin resistance will suffer
a more severe insulin resistance and finally glucose
intolerance in diabetes mellitus. With increasing
age and BMI, users tend to have more risk to suffer
insulin resistance.12 Parity is associated with insu-
lin resistance, this was due to chronic exposure of
hormones in pregnancy, in this case progesterone,
which causes insulin resistance. History of gesta-
tional diabetes mellitus are also risk for falls in a
state of diabetes mellitus because of defects that
have occurred due to pregnancy.4,6,8,9,13
The results of this study should be interpreted
with caution because it has several limitations,
among others were that the status of diabetes mel-
litus are known only in the case, whereas in the
control group there is no data for diabetes status.
That is, diabetes mellitus cases could be showing
more number when all of the subjects screened for
diabetes mellitus. Another weakness of this re-
search was that, we can only classify the subject
according to the contraceptive used only by the
longest type of contraceptive method they use, so
exposure to other contraceptives method could
also have influence. Another limitation that this
study did not measure lifestyle, which also plays
an important role in determining the occurrence of
diabetes mellitus.
Although this study showed the risk of diabetes
mellitus from the use DMPA injections, but the pur-
pose of this study should be examined carefully.
DMPA injection is one method of contraception
that is effective in preventing pregnancy, and res-
trictions on the use of DMPA injections to avoid
diabetes mellitus can lead to pregnancy, which in
itself increases the risk for the occurrence of dia-
betes mellitus.
This study aims to be a material consideration
for health providers, particularly health care cen-
ters associated with government programs to sup-
port family planning. With this research, the health
provider will be more selective for the selection of
candidates for DMPA injection acceptors. Candi-
dates for DMPA injection acceptors should be rated
for their risk of suffering diabetes mellitus. This se-
lection method will hopefully reduce the risk of
diabetes mellitus in users of DMPA injection.
Health centers and health personnel should per-
form a screening for diabetes mellitus before giving
DMPA injections. The examination should be per-
formed before the injection is started if possible.
Thus, the state of insulin resistance that has oc-
curred can be detected and further defect by DMPA
administration could be avoided.
CONCLUSION
There is a relationship between the use of DMPA
injections with the incidence of type 2 diabetes mel-
litus. Risk persists when adjusted for age and BMI.
Health providers need to do a selection for DMPA
users who have an increased risk to develop diabe-
tes mellitus. And when necessary, the user’s state
of insulin resistance have to be checked prior to use.
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